Amir Weiss - 24 Nov 2021 Form 3 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Chief Accounting Officer
Signature
/s/ Dov Bergwerk as attorney-in-fact for Amir Weiss
Issuer symbol
TEVA
Transactions as of
24 Nov 2021
Net transactions value
$0
Form type
3
Filing time
06 Dec 2021, 08:42:25 UTC
Next filing
02 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TEVA Ordinary Shares 14,391 24 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TEVA Restricted Share Units 24 Nov 2021 Ordinary Shares 14,258 Direct F1, F2, F3
holding TEVA Restricted Share Units 24 Nov 2021 Ordinary Shares 9,657 Direct F1, F3, F4
holding TEVA Restricted Share Units 24 Nov 2021 Ordinary Shares 4,809 Direct F1, F3, F5
holding TEVA Restricted Share Units 24 Nov 2021 Ordinary Shares 981 Direct F1, F3, F6
holding TEVA Stock Options (right to buy) 24 Nov 2021 Ordinary Shares 10,002 $19.16 Direct F1, F7
holding TEVA Stock Options (right to buy) 24 Nov 2021 Ordinary Shares 7,755 $34.70 Direct F1, F8
holding TEVA Stock Options (right to buy) 24 Nov 2021 Ordinary Shares 5,003 $53.50 Direct F1, F9
holding TEVA Stock Options (right to buy) 24 Nov 2021 Ordinary Shares 3,752 $60.21 Direct F1, F10
holding TEVA Stock Options (right to buy) 24 Nov 2021 Ordinary Shares 1,501 $48.76 Direct F1, F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 Restricted share units were granted on March 5, 2021, with 3,564 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 3,566 vesting on March 5, 2025.
F3 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F4 Restricted share units were granted on February 28, 2020 with 3,219 vesting on each of February 28, 2022, February 28, 2023 and February 28, 2024.
F5 Restricted share units were granted on March 4, 2019, with 2,403 vesting on March 4, 2022 and 2,406 vesting on March 4, 2023.
F6 Restricted share units were granted on March 3, 2018 and vest on March 2, 2022.
F7 Stock options were granted on March 3, 2018, with 2,500 having vested on each of March 2, 2019, March 2, 2020 and March 2, 2021 and 2,502 vesting on March 2, 2022.
F8 Stock options were granted on March 3, 2017, with 1,938 having vested on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 1,941 on March 3, 2021.
F9 Stock options were granted on March 17, 2016, with 1,250 having vested on each of March 17, 2017, March 17, 2018 and March 17, 2019 and 1,253 on March 17, 2020.
F10 Stock options were granted on March 12, 2015, with 938 having vested on each of March 12, 2016, March 12, 2017, March 12, 2018 and March 12, 2019.
F11 Stock options were granted on March 12, 2014, with 500 having vested on each of March 12, 2015 and March 12, 2016 and 501 having vested on March 12, 2017.

Remarks:

Exhibit 24 - Power of Attorney